GlassScriptPhysician profile
Zecharia Lind
NPI 1306894324
$7,495.57
in general payments reported to CMS, 2019-2025
22 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $1,030 · 2023: $1,369 · 2024: $2,908 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,881 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,880.63 |
| Education | $156.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,254.56 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $1,051.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $886.59 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $564.25 | 2021-2025 | Ilumya, Winlevi |
| Pfizer INC. | $531.99 | 2022-2025 | |
| Janssen Biotech, INC. | $477.06 | 2022-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $441.08 | 2023-2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $439.28 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $413.66 | 2021-2025 | |
| Dermavant Sciences, INC. | $396.90 | 2023-2024 | Vtama |
| Leo Pharma INC. | $265.38 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $145.91 | 2021-2024 | Cimzia, Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $129.79 | 2021-2024 | Jublia, Cabtreo |
| Organon LLC | $112.14 | 2024-2025 | Vtama, Hadlima |
| Journey Medical Corporation | $78.46 | 2022-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $77.22 | 2024-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $38.72 | 2025 | Dupixent |
| Lilly USA, LLC | $33.03 | 2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $29.86 | 2023-2025 | Zoryve |
| Biofrontera INC. | $28.93 | 2021 | |
| Mayne Pharma Commercial LLC | $27.72 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zecharia Lind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.